Navigation Links
Stantum Offering Demo, Evaluation & Development Board Based on Its Patented Resistive Multi-Touch Technology
Date:9/23/2008

First Such Board on the Market, Stantum's SMK Series Will Let Vendors Cost-Effectively Develop Their Own Resistive Multi-Touch Applications

SAN DIEGO, Sept. 23 /PRNewswire/ -- Stantum Technologies (http://www.stantum.com), a pioneer developer of multi-touch sensing technology, today introduced a demo, evaluation and development board based on its patented PMatrix(TM) resistive multi-touch technology, which lets users simultaneously move an unlimited number of fingers, nails or utensils (such as styli) on a screen.

The first such board on the market, the new SMK series enables vendors and OEMs to evaluate the performance of Stantum's technology and begin developing their own resistive multi-touch applications, thanks to a user-friendly interface compatible with Windows, MAC OS and Linux.

"Stantum is demonstrating that -- contrary to widespread misbelief -- multi-touch is possible with a cost-effective resistive touch-panel platform," said Chris Crotty, director of small and medium displays research at DisplaySearch, a leading provider of information, consulting and conferences on the display supply chain and display-related industries. "With this groundbreaking announcement, Stantum is combining the best of both worlds by offering the features of projected capacitive multi-touch with the lower cost and widespread availability of resistive touch technology."

Added Guillaume Largillier, Stantum's co-founder and CEO: "Our SMK series is the smart multi-touch development kit that the consumer electronics and other industries have long anticipated. It gives manufacturers developing their hardware and applications a great opportunity to assess the huge advantages that multi-touch capability can offer, especially when it uses resistive technology."

SMK boards come with either a 2.5- or 3.5-inch touch-panel sensor; a multi-touch controller; Stantum's Lemurofon software, for demonstr
'/>"/>

SOURCE Stantum
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology news :

1. Positron emission tomography superior to standard evaluation tools in measuring treatment response
2. Gender, coupled with diabetes, affects vascular disease development
3. New target for anti-flu drug development
4. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
5. KAUST and American University in Cairo to collaborate on research and academic development
6. Old developmental pathways spawn revolutionary evolutionary changes
7. NIST announces 56 new awards for innovative technology research and development
8. Progress Against Malaria: Developments on the Horizon
9. Flu vaccine in painless skin patches under development at Emory, Georgia Tech with NIH grants
10. Biopharmaceutical infrastructure key to lower drug development costs
11. Study identifies pathway required for normal reproductive development

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... snubbing? Your genetics, not your friends, may be...um-like painkillers, called opioids, relieve not o...l stress. Now, a new study reviewed by Faculty of ... genetic differences in the gene for the opioid re...ponses to social rejection. , In the study publ...
(Date:12/3/2009)...estment in energy efficient technologies research,...uncil (EPSRC) Chief Executive Dave Delpy believes ...esearch has already brought us fuel cells, marine,...nt is needed to develop the capabilities of differ...n targets by 2020 and limit the impact of climate ...
(Date:12/2/2009)...and cigarette smoke have an increased risk of deve...r smoked. , Results of this study are published..., a journal of the American Association for Cancer...he December issue. , This year alone, more than...cer; more than 159,000 will die from it and some o...
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels 12749 1Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels 12749 2Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels 12749 3Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels 12749 4Need something 3F Talk to my right ear 21 49772 1Need something 3F Talk to my right ear 21 49772 2Lack of happiness hormone serotonin in the brain causes impaired maternal behavior in mice 8972 1
...ockfish (Sebastes sp.) took place in the Central G...corporated fishery cooperatives instead of the usu...dicate increased retention rates, reduced bycatch ...ther benefits to the Kodiak Island community. , I... in slowing the pace of the fishery, improving pro...
... with blue eyes have a single, common ancestor. A ...down a genetic mutation which took place 6-10,000 ...l blue-eyed humans alive on the planet today. , ...l had brown eyes, said Professor Eiberg from the D... genetic mutation affecting the OCA2 gene in our c...
...ted to the framed journal covers decorating his of...ting, complicated structure of an enzyme. Those br...s lab. And theyre part of Reillys work to understa...echanism and its activity. , In other words, hes...work, said Reilly, a professor of chemical and bio...
Other Biology News:A pilot program for harvesting Kodiak rockfish 2A pilot program for harvesting Kodiak rockfish 3Blue-eyed humans have a single, common ancestor 2Iowa State researcher studies how enzymes break down cellulose 2
(Date:12/2/2009)... -- Reportlinker.com announces that a new market r..., Drug Discovery Technologies - A Global Update o.../www.reportlinker.com/p0164246/Drug-Discovery-Tech...tunities.html ,, Drug discovery has become an ...al company,s business strategy. There are a number...
(Date:12/2/2009)...FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics"...ced today that in connection with its previously a...cised in full their over-allotment option and purc...mprised of one common share and 0.4 of a common sh...S$3.00 per unit. Each whole common share purchase ...
(Date:12/2/2009)...ber 2 Gamida Cell announced today,...imal study) safety and,efficacy of a gene therapy ...ll Medical College and Gamida Cell. The product ma...s Cooley,s Anemia. , Gamida Cell is devel...,populations of stem/progenitor cells. The company...
(Date:12/2/2009)...stCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; T...al company focused on endocrine therapy and oncolo...ministration (FDA) has granted Fast Track designat...ompound, perifosine (KRX-0401), for the treatment ...pharmaceuticals, Inc. ("Keryx") ( KERX), is AEtern...
Breaking Biology Technology:Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3
...eb. 11 Caliper Life,Sciences, Inc. (Nasdaq: CALP...utsche Bank 2008 Small and Mid Cap Growth Conferen..., February 13 at 4:40 p.m. EST. Kevin,Hrusovsky, P...update on the,company,s business. The live webcast...reye/confLobby.zhtml?ticker=CALP&item_id=17485 ,73...
...s Potential New Short-Course Treatment Option for ...luding MRSA, CAMBRIDGE, Mass., Feb. 11 Targanta,...d today that it has,submitted a New Drug Applicati...(FDA) for its lead antibiotic candidate, oritavanc...otic candidate with potent,bactericidal (killing) ...
...e real-world clinical data on the PROMUS(TM) Stent...ration (NYSE: BSX ) today announced that the firs...(TM), ENdeavor(R) and CYpher(R)) European,registry...Olimus,-eluting,coronary stents. It will collect r...ic,s PROMUS(TM) Everolimus-Eluting Coronary Stent ...
Other Biology Technology:Targanta Submits Oritavancin New Drug Application 2Targanta Submits Oritavancin New Drug Application 3Targanta Submits Oritavancin New Drug Application 4Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 2Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 3Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 4
PCNA Immunohistochemistry Assay Kit from Invitrogen
Varian Cary 6000i Spectrophotometer from Varian, Inc.
Gln(Trt) Peptide Synthesis Column from Applied Biosystems
E. coli Expression System with Gateway Technology from Invitrogen
Biology Products: